- Home
- Publications
- Publication Search
- Publication Details
Title
Neuroprotective Effect of SGLT2 Inhibitors
Authors
Keywords
-
Journal
MOLECULES
Volume 26, Issue 23, Pages 7213
Publisher
MDPI AG
Online
2021-12-01
DOI
10.3390/molecules26237213
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
- (2021) David Bode et al. Cardiovascular Diabetology
- Protective effects of dapagliflozin against oxidative stress-induced cell injury in human proximal tubular cells
- (2021) Nawel Zaibi et al. PLoS One
- The Effects of SGLT2 Inhibitors on Lipid Metabolism
- (2021) Zsolt Szekeres et al. Metabolites
- Oxidative Stress in Vascular Pathophysiology: Still Much to Learn
- (2021) Guillermo Zalba Antioxidants
- Systemic Actions of SGLT2 Inhibition on Chronic mTOR Activation as a Shared Pathogenic Mechanism between Alzheimer’s Disease and Diabetes
- (2021) Gabriela Dumitrita Stanciu et al. Biomedicines
- Effects of Sodium‐Glucose Linked Transporter 2 Inhibition With Ertugliflozin on Mitochondrial Function, Energetics, and Metabolic Gene Expression in the Presence and Absence of Diabetes Mellitus in Mice
- (2021) Dominique Croteau et al. Journal of the American Heart Association
- Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
- (2021) A Young Sim et al. Frontiers in Neuroscience
- Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways
- (2021) Nami Lee et al. Journal of Immunology Research
- Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes
- (2021) Hongyan Liu et al. Kidney International Reports
- The SGLT2 inhibitor ertugliflozin causes a switch of cardiac substrate utilization leading to reduced cardiac mTOR-signaling, unfolded protein response and apoptosis
- (2021) J Moellmann et al. EUROPEAN HEART JOURNAL
- Investigating the Effects of Dapagliflozin on Cardiac Function, Inflammatory Response, and Cardiovascular Outcome in Patients with STEMI Complicated with T2DM after PCI
- (2021) LiMing Xue et al. Evidence-based Complementary and Alternative Medicine
- Brain-derived neurotrophic factor alleviates diabetes mellitus-accelerated atherosclerosis by promoting M2 polarization of macrophages through repressing the STAT3 pathway
- (2020) Changlong Bi et al. CELLULAR SIGNALLING
- SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action
- (2020) Milton Packer DIABETES CARE
- Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia/reperfusion injury through HIF-1α/VEGF signaling pathway
- (2020) Rania G. Abdel-latif et al. ARCHIVES OF PHARMACAL RESEARCH
- Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet–Induced Obese Mice
- (2020) Xiaodong Sun et al. DIABETES
- Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice
- (2020) Byambasuren Ganbaatar et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Type 3 Diabetes and Its Role Implications in Alzheimer’s Disease
- (2020) Thuy Trang Nguyen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Multifarious roles of mTOR signaling in cognitive aging and cerebrovascular dysfunction of Alzheimer's disease
- (2020) Md. Sahab Uddin et al. IUBMB LIFE
- Revisiting atherosclerosis and dementia
- (2020) Costantino Iadecola NATURE NEUROSCIENCE
- Shared proteomic effects of cerebral atherosclerosis and Alzheimer’s disease on the human brain
- (2020) Aliza P. Wingo et al. NATURE NEUROSCIENCE
- SGLT1 participates in the development of vascular cognitive impairment in a mouse model of small vessel disease
- (2020) Nanae Ishida et al. NEUROSCIENCE LETTERS
- SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease
- (2020) So Ra Kim et al. Nature Communications
- Sodium/glucose cotransporter 2 is expressed in choroid plexus epithelial cells and ependymal cells in human and mouse brains
- (2020) Yoichi Chiba et al. NEUROPATHOLOGY
- Glucose transporters in brain in health and disease
- (2020) Hermann Koepsell PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
- (2020) Thiquynhnga Nguyen et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Molecular abnormalities in autopsied brain tissue from the inferior horn of the lateral ventricles of nonagenarians and Alzheimer disease patients
- (2020) Andrew Pearson et al. BMC Neurology
- Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke
- (2020) Fatima Alzahra Al Hamed et al. CLINICAL THERAPEUTICS
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- (2020) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK–Akt–eNOS pathway in the isoprenaline-induced oxidative stress model
- (2020) Raquibul Hasan et al. Scientific Reports
- Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway
- (2020) Jun Zhou et al. BIOMEDICINE & PHARMACOTHERAPY
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer’s disease
- (2020) Niklas Lonnemann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
- (2019) Hiddo J. L. Heerspink et al. DIABETOLOGIA
- Tau accumulation triggers STAT1‐dependent memory deficits by suppressing NMDA receptor expression
- (2019) Xiao‐Guang Li et al. EMBO REPORTS
- Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
- (2019) Ghazaleh Behnammanesh et al. Frontiers in Pharmacology
- Understanding the Role of Systemic Inflammation in Alzheimer’s Disease
- (2019) Keenan A. Walker et al. ACS Chemical Neuroscience
- Systemic inflammation impairs microglial Aβ clearance through NLRP 3 inflammasome
- (2019) Dario Tejera et al. EMBO JOURNAL
- The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation
- (2019) Nathan Kelley et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Novel Insights Into the NLRP3 Inflammasome in Atherosclerosis
- (2019) Ying Jin et al. Journal of the American Heart Association
- Intersection of pathological tau and microglia at the synapse
- (2019) Thomas Vogels et al. Acta Neuropathologica Communications
- Association of ideal cardiovascular health at age 50 with incidence of dementia: 25 year follow-up of Whitehall II cohort study
- (2019) Séverine Sabia et al. BMJ-British Medical Journal
- Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update
- (2019) Giovanna Cenini et al. Frontiers in Pharmacology
- The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes
- (2019) Francesca Iannantuoni et al. Journal of Clinical Medicine
- Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet
- (2019) Liang Xu et al. BMJ Open Diabetes Research & Care
- Safety of Sodium-Glucose Co-Transporter 2 Inhibitors
- (2019) Janet B. McGill et al. AMERICAN JOURNAL OF CARDIOLOGY
- Macrophages in Atherosclerosis Regression
- (2019) Tessa J. Barrett ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy
- (2018) Mumin Alper Erdogan et al. BMC Neurology
- Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy
- (2018) Concetta Irace et al. Cardiovascular Diabetology
- Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017
- (2018) Thomas R. Einarson et al. Cardiovascular Diabetology
- A Perfect sTORm: The Role of the Mammalian Target of Rapamycin (mTOR) in Cerebrovascular Dysfunction of Alzheimer's Disease: A Mini-Review
- (2018) Candice E. Van Skike et al. GERONTOLOGY
- Role of mTOR in Glucose and Lipid Metabolism
- (2018) Zhuo Mao et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- RS1 (Rsc1A1) deficiency limits cerebral SGLT1 expression and delays brain damage after experimental traumatic brain injury
- (2018) Anne Sebastiani et al. JOURNAL OF NEUROCHEMISTRY
- Oxidative stress predicts cognitive decline with aging in healthy adults: an observational study
- (2018) Ihab Hajjar et al. Journal of Neuroinflammation
- Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis
- (2018) Muhammad Shariq Usman et al. European Journal of Preventive Cardiology
- SGLT2 Inhibitors and Mechanisms of Hypertension
- (2018) Alexandros Briasoulis et al. Current Cardiology Reports
- Validation of sodium/glucose cotransporter proteins in human brain as a potential marker for temporal narrowing of the trauma formation
- (2018) Sabrina Oerter et al. INTERNATIONAL JOURNAL OF LEGAL MEDICINE
- GSK3 and Tau: Two Convergence Points in Alzheimer's Disease
- (2018) Felix Hernandez et al. JOURNAL OF ALZHEIMERS DISEASE
- Neurovascular dysfunction in vascular dementia, Alzheimer’s and atherosclerosis
- (2018) Osman Shabir et al. BMC NEUROSCIENCE
- Sodium-glucose cotransporter inhibitors and oxidative stress: An update
- (2018) Habib Yaribeygi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- δ-Secretase-cleaved Tau stimulates Aβ production via upregulating STAT1-BACE1 signaling in Alzheimer’s disease
- (2018) Zhentao Zhang et al. MOLECULAR PSYCHIATRY
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium influx through cerebral sodium-glucose transporter type 1 exacerbates the development of cerebral ischemic neuronal damage
- (2017) Yui Yamazaki et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Mitochondrial dysfunction underlies cognitive defects as a result of neural stem cell depletion and impaired neurogenesis
- (2017) Mireille Khacho et al. HUMAN MOLECULAR GENETICS
- Molecular Interaction of Anti-Diabetic Drugs With Acetylcholinesterase and Sodium Glucose Co-Transporter 2
- (2017) Shazi Shakil JOURNAL OF CELLULAR BIOCHEMISTRY
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats
- (2017) Piangkwan Sa-nguanmoo et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Cardiovascular risk assessment in patients with diabetes
- (2017) Marcello Casaccia Bertoluci et al. Diabetology & Metabolic Syndrome
- Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
- (2017) Francesca Cinti et al. Drug Design Development and Therapy
- Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events
- (2017) Kenneth W. Mahaffey et al. CIRCULATION
- Perivascular Macrophages Limit PermeabilityHighlights
- (2016) Huanhuan He et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The role of cytokines in the development of atherosclerosis
- (2016) A. R. Fatkhullina et al. BIOCHEMISTRY-MOSCOW
- Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders
- (2016) Sibhghatulla Shaikh et al. BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY
- Predictionof Anti-Diabetic Drugs as Dual Inhibitors Against Acetylcholinesterase and Beta-Secretase: A Neuroinformatics Study
- (2016) Sibhghatulla Shaikh et al. CNS & Neurological Disorders-Drug Targets
- Alzheimer's disease: Targeting the Cholinergic System
- (2016) Talita H. Ferreira-Vieira et al. Current Neuropharmacology
- Perivascular macrophages mediate the neurovascular and cognitive dysfunction associated with hypertension
- (2016) Giuseppe Faraco et al. JOURNAL OF CLINICAL INVESTIGATION
- Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects
- (2016) Atsuo Tahara et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Atherosclerotic calcification is related to a higher risk of dementia and cognitive decline
- (2015) Daniel Bos et al. Alzheimers & Dementia
- Brain-derived neurotrophic factor and its clinical implications
- (2015) Siresha Bathina et al. Archives of Medical Science
- The blood–brain barrier endothelium: a target for pro-inflammatory cytokines: Figure 1
- (2015) Keith D. Rochfort et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- In-vivo imaging of grey and white matter neuroinflammation in Alzheimer’s disease: a positron emission tomography study with a novel radioligand, [18F]-FEPPA
- (2015) I Suridjan et al. MOLECULAR PSYCHIATRY
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
- (2014) Bowen Lin et al. Cardiovascular Diabetology
- Invokana (Canagliflozin) as a Dual Inhibitor of Acetylcholinesterase and Sodium Glucose Co-Transporter 2: Advancement in Alzheimer’s Disease- Diabetes Type 2 Linkage via an Enzoinformatics Study
- (2014) Syed Rizvi et al. CNS & Neurological Disorders-Drug Targets
- Atherosclerosis in epilepsy: Its causes and implications
- (2014) Sherifa A. Hamed EPILEPSY & BEHAVIOR
- Atherosclerosis and Alzheimer - diseases with a common cause? Inflammation, oxysterols, vasculature
- (2014) Richard Lathe et al. BMC Geriatrics
- Reactive Oxygen Species in Inflammation and Tissue Injury
- (2013) Manish Mittal et al. ANTIOXIDANTS & REDOX SIGNALING
- Clinical and Subclinical Macrovascular Disease as Predictors of Cognitive Decline in Older Patients With Type 2 Diabetes
- (2013) Insa Feinkohl et al. DIABETES CARE
- Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study
- (2013) Lieza G Exalto et al. Lancet Diabetes & Endocrinology
- The Role of Glucose Transporters in Brain Disease: Diabetes and Alzheimer's Disease
- (2012) Kaushik Shah et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Low BDNF is associated with cognitive deficits in patients with type 2 diabetes
- (2012) Yan Feng Zhen et al. PSYCHOPHARMACOLOGY
- Biology of Human Sodium Glucose Transporters
- (2011) Ernest M. Wright et al. PHYSIOLOGICAL REVIEWS
- Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI)
- (2009) Jessica B.S. Langbaum et al. NEUROIMAGE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started